A feasibility study of capecitabine plus oxaliplatin (CapeOX) and S-1 plus oxaliplatin (SOX) for unresectable advanced or reccurent gastric cancer
Not Applicable
- Conditions
- unresectable advanced or reccurent gastric cancer
- Registration Number
- JPRN-UMIN000015258
- Lead Sponsor
- Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Patients are excluded if they have HER-2 postive adenocarcinoma. HER-2 positivity is defined as IHC 3+ or IHC2+ and FISH-positive(HER2:CEP17 ratio over 2). Other exclusion criteria included uncontrolled infection, or uncontrolled significant comorbid conditions.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method